Sugi Predict

Sugi Predict / Compounds / SCHEMBL2998928

SCHEMBL2998928

SCHEMBL2998928

COc1ccc(CC(=O)Nc2ccc(Cl)c(NC3=NC(=O)/C(=C/c4ccc5ncccc5c4)S3)c2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.44
▸ MAPT P10636 5/20 0.43
▸ POLB P06746 3/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ CISD1 Q9NZ45 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ KDR P35968 2/20 0.41
▸ TP53 P04637 1/20 0.40
▸ CSF1R P07333 1/20 0.40
▸ RET P07949 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ KIT P10721 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ DDR1 Q08345 1/20 0.40
▸ ANO1 Q5XXA6 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998932 1.00 LMNA (0.44) LMNAMAPTPOLBKMT2AHPGD
SCHEMBL2996046 0.88 CISD1 (0.42) MAPTCISD1KDM4EANO1HTT
SCHEMBL2996047 0.88 CISD1 (0.42) MAPTCISD1KDM4EANO1HTT
SCHEMBL2996093 0.88 NOTUM (0.43) LMNAMAPTPOLBKMT2AHPGD
SCHEMBL2996091 0.88 NOTUM (0.43) LMNAMAPTPOLBKMT2AHPGD
SCHEMBL2993651 0.87 TSHR (0.42) LMNAMAPTPOLBKMT2AACHE
SCHEMBL2993647 0.87 TSHR (0.42) LMNAMAPTPOLBKMT2AACHE
SCHEMBL4942268 0.85 ALDH1A1 (0.43) LMNAMAPTPOLBKMT2AHPGD
Trifluoroacetic Acid SCHEMBL4089474 0.85 CISD1 (0.39) LMNAMAPTCISD1TP53ANO1
Trifluoroacetic Acid SCHEMBL4089468 0.85 CISD1 (0.39) LMNAMAPTCISD1TP53ANO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 — — US claimed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 — — US disclosed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 — — EP disclosed
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 — — US disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 — — WO disclosed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 — — EP disclosed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 LMNA 600/4885MAPT 721/4885POLB 991/4885
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 LMNA 1257/4885MAPT 1880/4885POLB 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.